CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 819 enrolled
Drug / intervention
insulin degludec/liraglutide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02607306
NCT02607306Phase 3Completed
CompareCT.gov

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/S·interventional·Posted Nov 18, 2015·Updated Apr 9, 2021

In Brief

A Phase 3 clinical trial evaluating insulin degludec/liraglutide, insulin degludec, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 819 participants across 76 sites.

Detailed Summary

This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide, insulin degludec and liraglutide in Japanese subjects with type 2 diabetes mellitus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 18, 2015
Enrollment StartNov 18, 2015
Primary CompletionDec 15, 2017
Study CompletionDec 22, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 10.6 years ago

Interventions

insulin degludec/liraglutidedrug

Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.

insulin degludecdrug

Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.

liraglutidedrug

Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.